These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 24195944)

  • 1. Exome sequencing: one small step for malignant hyperthermia, one giant step for our specialty--why exome sequencing matters to all of us, not just the experts.
    Nagele P
    Anesthesiology; 2013 Nov; 119(5):1006-8. PubMed ID: 24195944
    [No Abstract]   [Full Text] [Related]  

  • 2. Using exome data to identify malignant hyperthermia susceptibility mutations.
    Gonsalves SG; Ng D; Johnston JJ; Teer JK; Stenson PD; Cooper DN; Mullikin JC; Biesecker LG;
    Anesthesiology; 2013 Nov; 119(5):1043-53. PubMed ID: 24195946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exome sequencing reveals novel rare variants in the ryanodine receptor and calcium channel genes in malignant hyperthermia families.
    Kim JH; Jarvik GP; Browning BL; Rajagopalan R; Gordon AS; Rieder MJ; Robertson PD; Nickerson DA; Fisher NA; Hopkins PM
    Anesthesiology; 2013 Nov; 119(5):1054-65. PubMed ID: 24013571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics and pathophysiology of CACNA1S mutations in malignant hyperthermia.
    Beam TA; Loudermilk EF; Kisor DF
    Physiol Genomics; 2017 Feb; 49(2):81-87. PubMed ID: 28011884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the entire ryanodine receptor type 1 and alpha 1 subunit of the dihydropyridine receptor (CACNA1S) coding regions for variants associated with malignant hyperthermia in Australian families.
    Gillies RL; Bjorksten AR; Du Sart D; Hockey BM
    Anaesth Intensive Care; 2015 Mar; 43(2):157-66. PubMed ID: 25735680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical utility gene card for: malignant hyperthermia.
    Rosenberg H; Rueffert H
    Eur J Hum Genet; 2011 Jun; 19(6):. PubMed ID: 21248738
    [No Abstract]   [Full Text] [Related]  

  • 7. Malignant Hyperthermia, Exertional Heat Illness, and RYR1 Variants: The Muscle May Not Be the Brain.
    Sagui E
    Anesthesiology; 2016 Feb; 124(2):510. PubMed ID: 26785433
    [No Abstract]   [Full Text] [Related]  

  • 8. Screening for mutations in the RYR1 gene in families with malignant hyperthermia.
    Muniz VP; Silva HC; Tsanaclis AM; Vainzof M
    J Mol Neurosci; 2003; 21(1):35-42. PubMed ID: 14500992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In Reply.
    Hopkins PM; Fiszer D; Shaw MA; Roiz de Sa D
    Anesthesiology; 2016 Feb; 124(2):511. PubMed ID: 26785434
    [No Abstract]   [Full Text] [Related]  

  • 10. Exertional rhabdomyolysis and malignant hyperthermia in a patient with ryanodine receptor type 1 gene, L-type calcium channel alpha-1 subunit gene, and calsequestrin-1 gene polymorphisms.
    Capacchione JF; Sambuughin N; Bina S; Mulligan LP; Lawson TD; Muldoon SM
    Anesthesiology; 2010 Jan; 112(1):239-44. PubMed ID: 20010423
    [No Abstract]   [Full Text] [Related]  

  • 11. [Receptors, genetics and malignant hyperpyrexia].
    Shapira Y; Gurman GM
    Harefuah; 1997 Jun; 132(12):849-50. PubMed ID: 9264191
    [No Abstract]   [Full Text] [Related]  

  • 12. Ryanodine receptor gene (RYR1) mutations for diagnosing susceptibility to malignant hyperthermia.
    Urwyler A; Halsall PJ; Mueller C; Robinson R
    Acta Anaesthesiol Scand; 2003 Apr; 47(4):492; author reply 493. PubMed ID: 12694155
    [No Abstract]   [Full Text] [Related]  

  • 13. [Malignant hyperthermia as a complication of anesthesia: predisposition is hereditary].
    Snoeck MM; Gielen MJ; Sengers RC; Padberg GW; Iles DE; Booij LH
    Ned Tijdschr Geneeskd; 1997 Mar; 141(13):616-9. PubMed ID: 9190536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Central core disease and susceptibility to malignant hyperthermia in a single family.
    Colleoni L; Melli G; Morandi L; Cudia P; Romaggi S; Mantegazza R; Bernasconi P
    J Neurol; 2009 Jul; 256(7):1161-3. PubMed ID: 19252784
    [No Abstract]   [Full Text] [Related]  

  • 15. Malignant hyperthermia.
    Bouchama A; Hussain S
    Lancet; 1998 Nov; 352(9142):1785. PubMed ID: 9848381
    [No Abstract]   [Full Text] [Related]  

  • 16. No C1840 to T mutation in RYR1 in malignant hyperthermia.
    Hall-Curran JL; Stewart AD; Ball SP; Halsall JP; Hopkins PM; Ellis FR
    Hum Mutat; 1993; 2(4):330. PubMed ID: 8401544
    [No Abstract]   [Full Text] [Related]  

  • 17. Perinatal diagnosis of malignant hyperthermia susceptibility.
    Girard T; Jöhr M; Schaefer C; Urwyler A
    Anesthesiology; 2006 Jun; 104(6):1353-4. PubMed ID: 16732128
    [No Abstract]   [Full Text] [Related]  

  • 18. DNA testing for malignant hyperthermia: the reality and the dream.
    Stowell KM
    Anesth Analg; 2014 Feb; 118(2):397-406. PubMed ID: 24445638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Malignant hyperthermia: a pharmacogenetic disorder.
    Stratman RC; Flynn JD; Hatton KW
    Orthopedics; 2009 Nov; 32(11):835. PubMed ID: 19902883
    [No Abstract]   [Full Text] [Related]  

  • 20. Skeletal muscle ryanodine receptor mutations associated with malignant hyperthermia showed enhanced intensity and sensitivity to triggering drugs when expressed in human embryonic kidney cells.
    Sato K; Roesl C; Pollock N; Stowell KM
    Anesthesiology; 2013 Jul; 119(1):111-8. PubMed ID: 23459219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.